Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Melanoma 8Neoplasms 2Recurrence 1Melanoma, Cutaneous Malignant 1Lymphoma 1Locally Advanced Melanoma 1Central Nervous System Neoplasms 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 23Radiosurgery 21Temozolomide 14Bevacizumab 12pembrolizumab 10Specimen Handling 9Nivolumab 8Radiotherapy 7Ipilimumab 7Magnetic Resonance Imaging 6Cyclophosphamide 5Capecitabine 5Blood Specimen Collection 5encorafenib 4Radiation 4Neuropsychological Tests 4Mental Status and Dementia Tests 4Memantine 4Carboplatin 4fludarabine 3fluciclovine F-18 3binimetinib 3abemaciclib 3Watchful Waiting 3Proton Therapy 3Etoposide 3Dexamethasone 3Adrenal Cortex Hormones 3trastuzumab deruxtecan 2sacituzumab govitecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Brain Neoplasms × Opdualag × Clear all
NCT06712927 2026-05-18

Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

Stanford University

Phase 2 Recruiting
60 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡